Last reviewed · How we verify
ISIS EIF4E Rx
At a glance
| Generic name | ISIS EIF4E Rx |
|---|---|
| Sponsor | Ionis Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC) (PHASE1, PHASE2)
- Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ISIS EIF4E Rx CI brief — competitive landscape report
- ISIS EIF4E Rx updates RSS · CI watch RSS
- Ionis Pharmaceuticals, Inc. portfolio CI